INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 179 filers reported holding INTRA CELLULAR THERAPIES INC in Q3 2021. The put-call ratio across all filers is 0.27 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $3,375,000 | -4.2% | 90,531 | +4.9% | 0.42% | -8.0% |
| Q2 2021 | $3,522,000 | +42.9% | 86,281 | +18.8% | 0.46% | +137.1% |
| Q1 2021 | $2,465,000 | +9.7% | 72,648 | +2.7% | 0.19% | +4.3% |
| Q4 2020 | $2,248,000 | +48.7% | 70,705 | +20.0% | 0.19% | +32.9% |
| Q3 2020 | $1,512,000 | +192.5% | 58,935 | +192.5% | 0.14% | +164.2% |
| Q2 2020 | $517,000 | – | 20,150 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $42,833,000 | 8.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 308,819 | $18,897,000 | 7.82% |
| Vahanian & Associates Financial Planning Inc. | 45,533 | $2,786,000 | 6.44% |
| DCF Advisers, LLC | 238,500 | $14,594,000 | 6.39% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 50,956 | $20,930,000 | 4.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,531,923 | $93,738,000 | 2.86% |
| Nicholas Investment Partners, LP | 562,373 | $34,412,000 | 2.45% |
| Bellevue Group AG | 3,429,619 | $209,859,000 | 2.44% |
| WASATCH ADVISORS LP | 7,477,868 | $457,571,000 | 2.25% |
| Quantum Private Wealth, LLC | 73,772 | $4,514,000 | 1.95% |